ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0806

Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 1042

Long-term Safety of Ixekizumab in Adult Patients with Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis

Spondyloarthritis Including PsA – Treatment Poster II: Mixed

9:00AM-10:30AM: Abstract Number: 1088

Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0782

Low Circulating B Cells Correlate with Unresponsiveness to COVID-19 Vaccination Among Patients Treated with Rituximab

Infection-related Rheumatic Disease Poster

9:00AM-10:30AM: Abstract Number: 1027

Low Dose Computed Tomography Hounsfield Units: A Reliable Methodology for Assessing Changes in Vertebral Bone Density in Radiographic Axial Spondyloarthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0693

Low Neutrophil Ectonucleotidase Activity Drives Neutrophil-Platelet Aggregation and Platelet Activation in Antiphospholipid Syndrome (APS)

Antiphospholipid Syndrome Poster

9:00AM-10:30AM: Abstract Number: 0976

Low-dose Belimumab and Antimalarial Agents Prevent Renal Flares in Systemic Lupus Erythematosus: Results from Four Randomised Clinical Trials

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 1062

Lung Magnetic Resonance Imaging in Systemic Sclerosis Associated Interstitial Lung Disease: Potentiality and Comparison with Other Imaging Techniques

Systemic Sclerosis and Related Disorders – Clinical Poster I

9:00AM-10:30AM: Abstract Number: 0645

Lupus Fibroblasts from Non-lesional Skin Exhibit Exaggerated Responses to Inflammatory Cytokines and Upregulate Pro-fibrotic Collagens in Patients with Scarring Lesions

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0654

Lymphatic Dysfunction and Immune Activation in Lupus

SLE – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0830

Lymphopenia as a Marker of Disease Activity and Severity in Sarcoidosis

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0609

Macrophage Response to MAA Modified Fibrinogen in the Presence of Peptidyl Arginine Deiminase Inhibitor

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0831

Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0748

Mapping Long COVID-19 Patient Journeys for Rheumatic Disease Patients

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0606

Mechanism of Joint-Specific Homeobox D10 Regulation in Rheumatoid Arthritis Fibroblast-Like Synoviocytes

RA – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].